Eli Lilly & Co.’s Zepbound is helping to solve one of the most intractable health challenges of our time: Obesity. Now, the drugmaker hopes to crack another significant public health problem: Sleep disorders.

AstraZeneca Plc’s profit rose more than analysts anticipated last quarter, buoyed by demand for its blockbuster cancer and diabetes drugs.

Novo Nordisk A/S made an unsolicited bid for US biotech firm Metsera Inc., sparking a heated battle with Pfizer Inc. to get their hands on weight-loss treatments that both drugmakers want in order to regain lost ground in the booming market.

AI drug developer Recursion Pharmaceuticals Inc. is considering an Amazon Prime-style subscription model for selling its pipeline of medicines.

As pharma giants spend billions on acquisitions of startups developing new ways to harness radiation in the fight against cancer, the chief executive officer of Perspective Therapeutics Inc. found himself getting top billing at two different industry gatherings this week.